This application outlines the establishment of the Rochester, New York and an International Unit in Rio de Janeiro, Brazil. The two Units are highly complementary and blend the expertise and experience of two very successful ongoing programs: the AVEU at the University of Rochester (UR) and the HIVNET site at the Universidade Federal do Rio de Janeiro (UFRJ). The UR AVEU has over ten years of experience in the performance of preventive HIV vaccine trials, with an emphasis on Phase I/II investigations, whereas the UFRJ HIVNET has developed expertise in the establishment of cohorts at high-risk of HIV infection, and in the conduct of large scale clinical trials. Investigators at both the Domestic and International Units cave made major scientific and administrative contributions directly relevant to the progress of HIV vaccine research, .and plan to continue this tradition in the HVTN. The proposed HVTU will contribute actively to the HVTN Scientific agenda, and will conduct Phase I, II, and III investigations of candidate HIV vaccines in both domestic and international settings. The Rochester-Rio HVTU investigators plan to propose, chair, and participate in protocols that evaluate (l) novel immunogens designed to stimulate neutralizing antibodies against primary isolates, (2) vaccine candidates designed to induce high levels of CTL activity and other cellular responses, (3) approaches to improvement if mucosal immunity, (4) replicating viral and bacterial vectors, (5) different routes of vaccine administration, (6) new inmunologic assays, and (7) the impact of host factors and viral variation on vaccine efficacy. In the first year of the project period, the Rochester-Rio HVTU plans to participate in 6 Phase I and 2 Phase II HIV vaccine trials, and to enroll 150 subjects, including 90 at low risk for HIV infection and 60 at high risk. Rochester- Rio investigators also -tend to participate actively in Phase III studies as they become available, and have presented an expansion plan that will draw on a total population base of nearly 19 million people and enable the HVTU to easily enroll 1,000 subjects annually in efficacy trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI047980-04
Application #
6651967
Study Section
Special Emphasis Panel (ZAI1-HSD-A (M1))
Program Officer
Yoder, Christian P
Project Start
2000-06-01
Project End
2005-05-31
Budget Start
2003-06-01
Budget End
2004-05-31
Support Year
4
Fiscal Year
2003
Total Cost
$1,388,773
Indirect Cost
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Frey, Sharon E; Peiperl, Laurence; McElrath, M Juliana et al. (2014) Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. Clin Vaccine Immunol 21:1589-99
Wecker, M; Gilbert, P; Russell, N et al. (2012) Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin Vaccine Immunol 19:1651-60
Churchyard, Gavin J; Morgan, Cecilia; Adams, Elizabeth et al. (2011) A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 6:e21225
Keefer, Michael C; Frey, Sharon E; Elizaga, Marnie et al. (2011) A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 29:1948-58
de Bruyn, Guy; Hudgens, Michael G; Sullivan, Patrick S et al. (2005) Participant retention in clinical trials of candidate HIV vaccines. J Acquir Immune Defic Syndr 39:499-501
Goepfert, Paul A; Horton, Helen; McElrath, M Juliana et al. (2005) High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 192:1249-59
Chen, Huiyuan; Reichman, Richard; Keefer, Michael et al. (2005) Establishment of an alternative intracellular cytokine staining assay for HIV/AIDS clinical studies. J Virol Methods 123:131-40
Lee, Deborah; Graham, Barney S; Chiu, Ya-Lin et al. (2004) Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 190:903-7
Horton, Helen; Russell, Nina; Moore, Erin et al. (2004) Correlation between interferon- gamma secretion and cytotoxicity, in virus-specific memory T cells. J Infect Dis 190:1692-6
de Bruyn, Guy; Rossini, Anthony J; Chiu, Ya-Lin et al. (2004) Safety profile of recombinant canarypox HIV vaccines. Vaccine 22:704-13